Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Glucotrack (NASDAQ: GCTK) has partnered with OneTwo Analytics AB to analyze clinical study data for its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. The collaboration aims to evaluate the performance and clinical value of Glucotrack's innovative CBGM technology.
Unlike traditional monitors that measure glucose in interstitial fluid, Glucotrack's CBGM is a long-term implantable device that measures glucose directly from blood, providing real-time readings without lag time. The device operates without external components and is designed to offer three years of continuous monitoring.
Through this partnership, OneTwo Analytics will apply their expertise in diabetes data analysis to identify and assess the long-term benefits of the CBGM technology. The collaboration focuses on developing a comprehensive ecosystem combining blood glucose insights, risk stratification data, patient engagement tools, and clinical dashboards.
Glucotrack (NASDAQ: GCTK) ha stipulato una partnership con OneTwo Analytics AB per analizzare i dati degli studi clinici per il suo Monitoraggio Continuo della Glucosio nel Sangue (CBGM) utilizzando analisi basate su intelligenza artificiale. La collaborazione mira a valutare le prestazioni e il valore clinico della tecnologia innovativa di CBGM di Glucotrack.
Contrariamente ai monitor tradizionali che misurano il glucosio nel fluido interstiziale, il CBGM di Glucotrack è un dispositivo impiantabile a lungo termine che misura il glucosio direttamente dal sangue, fornendo letture in tempo reale senza ritardi. Il dispositivo funziona senza componenti esterni ed è progettato per offrire tre anni di monitoraggio continuo.
Grazie a questa partnership, OneTwo Analytics applicherà la propria esperienza nell'analisi dei dati diabetici per identificare e valutare i benefici a lungo termine della tecnologia CBGM. La collaborazione si concentra sullo sviluppo di un ecosistema completo che combina approfondimenti sul glucosio nel sangue, dati di stratificazione del rischio, strumenti di coinvolgimento dei pazienti e dashboard cliniche.
Glucotrack (NASDAQ: GCTK) se ha asociado con OneTwo Analytics AB para analizar los datos de estudios clínicos de su Monitor de Glucosa en Sangre Continuo (CBGM) utilizando análisis impulsados por inteligencia artificial. La colaboración tiene como objetivo evaluar el rendimiento y el valor clínico de la innovadora tecnología CBGM de Glucotrack.
A diferencia de los monitores tradicionales que miden la glucosa en el líquido intersticial, el CBGM de Glucotrack es un dispositivo implantable a largo plazo que mide la glucosa directamente de la sangre, proporcionando lecturas en tiempo real sin tiempos de espera. El dispositivo funciona sin componentes externos y está diseñado para ofrecer tres años de monitoreo continuo.
A través de esta asociación, OneTwo Analytics aplicará su experiencia en el análisis de datos de diabetes para identificar y evaluar los beneficios a largo plazo de la tecnología CBGM. La colaboración se centra en desarrollar un ecosistema integral que combine información sobre la glucosa en sangre, datos de estratificación de riesgos, herramientas de compromiso del paciente y paneles clínicos.
글루코트랙 (NASDAQ: GCTK)은 원투 애널리틱스 AB와 협력하여 인공지능 기반 분석을 사용하여 지속적인 혈당 모니터(CBGM)의 임상 연구 데이터를 분석합니다. 이 협업은 글루코트랙의 혁신적인 CBGM 기술의 성능과 임상 가치를 평가하는 것을 목표로 합니다.
전통적인 모니터가 간질액에서 포도당을 측정하는 것과 달리, 글루코트랙의 CBGM은 장기 이식 가능한 장치로, 혈액에서 직접 포도당을 측정하여 지연 없이 실시간으로 읽기를 제공합니다. 이 장치는 외부 구성 요소 없이 작동하며, 3년간의 지속적인 모니터링을 제공하도록 설계되었습니다.
이 파트너십을 통해 원투 애널리틱스는 당뇨병 데이터 분석에 대한 전문성을 활용하여 CBGM 기술의 장기적 이점을 식별하고 평가할 것입니다. 협업은 혈당 통찰력, 위험 계층화 데이터, 환자 참여 도구 및 임상 대시보드를 결합한 포괄적인 생태계 개발에 중점을 두고 있습니다.
Glucotrack (NASDAQ: GCTK) s'est associé à OneTwo Analytics AB pour analyser les données d'études cliniques de son Moniteur de Glucose Sanguin Continu (CBGM) en utilisant des analyses basées sur l'intelligence artificielle. La collaboration vise à évaluer la performance et la valeur clinique de la technologie innovante de CBGM de Glucotrack.
Contrairement aux moniteurs traditionnels qui mesurent le glucose dans le liquide interstitiel, le CBGM de Glucotrack est un dispositif implantable à long terme qui mesure le glucose directement dans le sang, fournissant des lectures en temps réel sans temps de latence. L'appareil fonctionne sans composants externes et est conçu pour offrir trois ans de surveillance continue.
Grâce à ce partenariat, OneTwo Analytics appliquera son expertise en analyse de données sur le diabète pour identifier et évaluer les avantages à long terme de la technologie CBGM. La collaboration se concentre sur le développement d'un écosystème complet combinant des informations sur le glucose sanguin, des données de stratification des risques, des outils d'engagement des patients et des tableaux de bord cliniques.
Glucotrack (NASDAQ: GCTK) hat sich mit OneTwo Analytics AB zusammengeschlossen, um die Daten klinischer Studien für seinen kontinuierlichen Blutzucker-Monitor (CBGM) mithilfe von KI-gesteuerten Analysen zu analysieren. Die Zusammenarbeit zielt darauf ab, die Leistung und den klinischen Wert der innovativen CBGM-Technologie von Glucotrack zu bewerten.
Im Gegensatz zu traditionellen Monitoren, die Glukose im interstitiellen Fluid messen, ist Glucotracks CBGM ein langfristig implantierbares Gerät, das Glukose direkt aus dem Blut misst und in Echtzeit ohne Verzögerung liefert. Das Gerät arbeitet ohne externe Komponenten und ist darauf ausgelegt, drei Jahre kontinuierliche Überwachung zu bieten.
Durch diese Partnerschaft wird OneTwo Analytics seine Expertise in der Analyse von Diabetesdaten anwenden, um die langfristigen Vorteile der CBGM-Technologie zu identifizieren und zu bewerten. Die Zusammenarbeit konzentriert sich auf die Entwicklung eines umfassenden Ökosystems, das Einblicke in den Blutzucker, Risikostratifizierungsdaten, Patientenengagement-Tools und klinische Dashboards kombiniert.
- Innovative technology measuring glucose directly from blood instead of interstitial fluid
- Long-term implantable device lasting 3 years with no external components
- Partnership with AI analytics firm to enhance clinical study data analysis
- Development of comprehensive ecosystem for diabetes management
- Product still in clinical study phase, not yet commercialized
- Long-term performance and safety data not yet available
Insights
This partnership with OneTwo Analytics represents a strategically sound move for Glucotrack's development of their Continuous Blood Glucose Monitor (CBGM). The collaboration targets a critical aspect of product development—extracting maximum value from clinical study data through advanced analytics.
Glucotrack's CBGM technology offers several potential advantages over traditional continuous glucose monitors: direct blood measurement versus interstitial fluid sampling, elimination of the typical measurement lag time, a fully implantable design with no external components, and an impressive three-year functional lifespan. These differentiating factors could position the device as a disruptive alternative in the competitive glucose monitoring market.
For a company with Glucotrack's market size (
However, this announcement lacks critical details that would enable assessment of near-term impact. The current status of clinical trials, regulatory timeline, and partnership financial terms remain undisclosed. While improved analytics capabilities may strengthen Glucotrack's development program, the fundamental success factors—clinical efficacy, safety profile, and regulatory approval—remain dependent on the underlying trial results rather than the analysis methodology.
The Glucotrack-OneTwo Analytics collaboration highlights a growing recognition of advanced data analytics' importance in clinical research. By applying AI and machine learning to clinical study data, Glucotrack may uncover subtle patterns and deeper insights that conventional analysis might miss.
The CBGM technology's direct blood measurement approach addresses a significant limitation in current CGM devices—the lag time associated with interstitial fluid glucose monitoring. This lag can delay detection of rapid glucose changes, particularly problematic during hypoglycemic events or post-meal spikes. An accurate, lag-free monitoring system would represent a meaningful clinical advancement.
However, the value of sophisticated analytics depends entirely on the quality of the underlying data. The press release provides no information about the current stage of clinical testing, study design, or preliminary results. Without these details, it's impossible to assess whether this partnership will accelerate development timelines or merely provide more thorough analysis of already-scheduled study data.
For implantable devices, durability, biocompatibility, and calibration stability over the three-year lifespan are critical success factors. Advanced analytics may help evaluate these parameters, but cannot overcome fundamental technical challenges if they exist. The announcement suggests progression in Glucotrack's development program but represents just one component in a complex, multi-stage process toward potential commercialization.
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced an agreement with OneTwo Analytics AB, a leading healthtech company specializing in AI-driven analytics for diabetes data including continuous glucose monitoring (CGM), diabetes technology stack development, and clinical study data analysis. Through this collaboration, Glucotrack will leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its Continuous Blood Glucose Monitor (CBGM), enhancing insights into its performance and clinical value.
Unlike traditional continuous glucose monitors that measure glucose levels in interstitial fluid, the CBGM measures glucose directly from blood, aiming to provide real-time readings without the lag time typically associated with interstitial glucose measurements. The CBGM is a long-term implantable device with no on-body external component. It is designed to provide three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution.
“OneTwo Analytics are experts in simplifying complex diabetes data to generate simple, clear insights empowering clinics, healthcare professionals, and individuals with diabetes to make better informed decisions. We are excited to leverage their substantial analytics experience to identify, assess and quantify the potential long-term benefits of the CBGM technology,” stated Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We are committed to building on our robust suite of preclinical and in silico data by utilizing their comprehensive analytical and AI assessment tools, thereby ensuring our ability to deliver a disruptive, high-quality glucose monitoring solution to people with diabetes.”
Steven Pusterla, Chief Commercial Officer of OneTwo Analytics said: “This collaboration with Glucotrack marks a significant step in our mission to leverage data and technology to transform diabetes management. By integrating our expertise in clinical study analysis with Glucotrack’s groundbreaking glucose monitoring technology, we are poised to deliver a truly end-to-end solution for both healthcare providers and patients. We are excited to expand our efforts through the development of a comprehensive ecosystem that combines blood glucose insights, risk stratification data, patient engagement tools, and actionable clinical dashboards. Together, we aim to revolutionize diabetes management and improve care for the millions of people navigating life with diabetes every day.”
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
For more information about OneTwo Analytics AB, visit onetwo-analytics.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
About OneTwo Analytics
OneTwo Analytics is a leader in AI-driven healthcare solutions, specializing in the analysis of diabetes data, real-world evidence, and clinical trial outcomes. The company develops advanced diabetes technology stacks for device manufacturers while recently launching a suite of solutions that are empowering healthcare providers and patients with data-driven intelligence to simplify diabetes disease management and improve efficiencies and outcomes.
OneTwo Analytics’ innovative tools provide healthcare professionals with valuable perspectives for personalized and efficient care, while also offering tailored solutions for stakeholders in the diabetes care sector. The company delivers a comprehensive Diabetes Technology Stack and White-Label solutions for organizations specializing in diabetes technologies.
For more information, please visit https://onetwo-analytics.com/en/.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
What makes Glucotrack's CBGM (GCTK) different from traditional glucose monitors?
How long does Glucotrack's (GCTK) blood glucose monitor last once implanted?
What will OneTwo Analytics provide for Glucotrack's (GCTK) clinical studies?
What are the key features of Glucotrack's (GCTK) CBGM device?
